Company Filing History:
Years Active: 2014
Title: Inventor Spotlight: Daniela Stoellner
Introduction:
Daniela Stoellner, based in Basel, Switzerland, is a notable inventor recognized for her significant contributions to the field of biotechnology. With one patent to her name, she has made strides in the development of high-specificity antibodies that have the potential to impact pharmacokinetic and pharmacodynamic assessments.
Latest Patents:
Daniela's patent, titled "Antibodies to modified human IGF-1/E peptides," focuses on creating antibodies capable of distinctly identifying modified human IGF-1 proteins from their wild-type counterparts. This innovative work ensures that her antibodies show minimal cross-reactivity with similar proteins in both humans and rodents. Such precision can play a pivotal role in evaluating the effects of IGF-1/E peptides in clinical and research settings.
Career Highlights:
Currently, Daniela is employed at Novartis AG, a leading global healthcare company. Her work within Novartis has allowed her to collaborate with various professionals in her field, significantly enhancing her research foundation and expertise. She has played a crucial role in advancing antibody technology, which holds promise for numerous biomedical applications.
Collaborations:
Throughout her career, Daniela has collaborated with talented colleagues, including Mara Fornaro and John Xu. These partnerships have not only fostered a rich exchange of ideas and knowledge but have also propelled joint projects that strive for excellence in the realm of therapeutic development.
Conclusion:
Daniela Stoellner’s innovative approach to developing high-specificity antibodies showcases her valuable contributions to biotechnology. As her career unfolds, her efforts will likely usher in advancements that benefit both clinical applications and research methodologies in understanding and treating various health conditions.